acetyl tert-butyl dimethylindan: musk fragrance; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 61585 |
| CHEMBL ID | 3188960 |
| CHEBI ID | 172483 |
| SCHEMBL ID | 112943 |
| MeSH ID | M0102920 |
| Synonym |
|---|
| 1-(6-tert-butyl-1,1-dimethyl-2,3-dihydro-1h-inden-4-yl)ethanone |
| STK709219 |
| 1-(6-tert-butyl-1,1-dimethyl-2,3-dihydroinden-4-yl)ethanone |
| CHEBI:172483 |
| einecs 236-114-4 |
| ketone, 6-tert-butyl-1,1-dimethyl-4-indanyl methyl |
| ai3-28573 |
| ethanone, 1-(6-(1,1-dimethylethyl)-2,3-dihydro-1,1-dimethyl-1h-inden-4-yl)- |
| 6-tert-butyl-1,1-dimethylindan-4-yl methyl ketone |
| 1-(6-(1,1-dimethylethyl)-2,3-dihydro-1,1-dimethyl-1h-inden-4-yl)ethanone |
| 6-tert-butyl-1,1-dimethyl-4-indanyl methyl ketone |
| 4-acetyl-6-butyl-1,1-dimethylindane |
| fema no. 3653 |
| 4-acetyl-6-tert-butyl-1,1-dimethylindane |
| celestolide |
| 4-acetyl-6-tert-butyl-1,1-dimethyl indan |
| ethanone, 1-[6-(1,1-dimethylethyl)-2,3-dihydro-1,1-dimethyl-1h-inden-4-yl]- |
| SR-01000639907-1 |
| 13171-00-1 |
| 4-acetyl-6-tert-butyl-1,1-dimethylindan |
| AKOS001014891 |
| A806300 |
| dtxcid7024536 |
| tox21_301542 |
| dtxsid9044536 , |
| cas-13171-00-1 |
| NCGC00255757-01 |
| BBL009811 |
| CCG-50538 |
| ccris 8404 |
| acetyl tert-butyl dimethylindan |
| hsdb 8415 |
| e1hm68q21p , |
| unii-e1hm68q21p |
| FT-0601565 |
| 4-acetyl-6-tert-butyl-1,1-dimethylindane [fhfi] |
| acetyl-6-tert-butyl-1,1-dimethylindane, 4- |
| crysolide |
| musk dimethyl indane |
| SCHEMBL112943 |
| 1-(6-tert-butyl-1,1-dimethyl-indan-4-yl)-ethanone |
| 4-acetyl-6-t-butyl-1,1-dimethylindane |
| mfcd00046324 |
| 1-(6-(tert-butyl)-1,1-dimethyl-2,3-dihydro-1h-inden-4-yl)ethanone |
| indane, 4-acetyl-1,1-dimethyl-6-(1,1-dimethylethyl) |
| W-110316 |
| PS-7533 |
| 1-(6-tert-butyl-1,1-dimethyl-2,3-dihydro-1h-inden-4-yl)ethan-1-one |
| CHEMBL3188960 |
| c17h24o |
| 1-[6-(1,1-dimethylethyl)-2,3-dihydro-1,1-dimethyl-1h-inden-4-yl]-ethanone; |
| adbi 10 microg/ml in cyclohexane |
| 4-acetyl-1,1-dimethyl-6-t-butylindane |
| fema 3653 |
| esperone |
| musk celestolide |
| 6-tert-butyl-1,1-dimethyl-4-indanyl methyl ketone, 8ci |
| 1-[6-(1,1-dimethylethyl)-2,3-dihydro-1,1-dimethyl-1h-inden-4-yl]ethanone, 9ci |
| chrysolide |
| AMY22339 |
| D70472 |
| Q27276748 |
| adbi |
| CS-0155127 |
| EN300-6503878 |
| Z56807661 |
| Class | Description |
|---|---|
| indanes | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 27.3060 | 0.0010 | 22.6508 | 76.6163 | AID1224839 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 61.6448 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 10.8681 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 29.7809 | 0.0002 | 29.3054 | 16,493.5996 | AID743080; AID743091 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 68.5896 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 0.0062 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 43.6412 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 49.2911 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 47.6437 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 61.6448 | 0.0420 | 27.3789 | 61.6448 | AID743210 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 48.5577 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.05) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||